

RealRate

PHARMACEUTICAL 2023

Xenon Pharmaceuticals Inc. Rank 15 of 446





🖁 XENON





Xenon Pharmaceuticals Inc. Rank 15 of 446

The relative strengths and weaknesses of Xenon Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenon Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Xenon Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 283%, being 240% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	600,298
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,702
Liabilities, Non-Current	9,947
Other Assets	147,348
Other Compr. Net Income	-2,010
Other Expenses	118
Other Liabilities	0
Other Net Income	3,888
Other Revenues	9,434
Property and Equipment	6,500
Research and Development	105,767
Selling, General and Administrative Expense	32,810

Output Variable	Value in 1000 USD
Assets	754,146
Liabilities	32,649
Expenses	138,695
Revenues	9,434
Stockholders Equity	721,497
Net Income	-125,373
Comprehensive Net Income	-126,378
Economic Capital Ratio	283%

